SG11202112329RA - Anti-abeta vaccine therapy - Google Patents
Anti-abeta vaccine therapyInfo
- Publication number
- SG11202112329RA SG11202112329RA SG11202112329RA SG11202112329RA SG11202112329RA SG 11202112329R A SG11202112329R A SG 11202112329RA SG 11202112329R A SG11202112329R A SG 11202112329RA SG 11202112329R A SG11202112329R A SG 11202112329RA SG 11202112329R A SG11202112329R A SG 11202112329RA
- Authority
- SG
- Singapore
- Prior art keywords
- vaccine therapy
- abeta vaccine
- abeta
- therapy
- vaccine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19175810 | 2019-05-21 | ||
| EP19185593 | 2019-07-10 | ||
| EP20171549 | 2020-04-27 | ||
| EP20172205 | 2020-04-29 | ||
| PCT/EP2020/064172 WO2020234405A1 (en) | 2019-05-21 | 2020-05-20 | Anti-abeta vaccine therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202112329RA true SG11202112329RA (en) | 2021-12-30 |
Family
ID=70740677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202112329RA SG11202112329RA (en) | 2019-05-21 | 2020-05-20 | Anti-abeta vaccine therapy |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220226447A1 (de) |
| EP (1) | EP3972633A1 (de) |
| JP (1) | JP2022533422A (de) |
| KR (1) | KR20220010552A (de) |
| CN (1) | CN113853214A (de) |
| AU (1) | AU2020277682A1 (de) |
| BR (1) | BR112021023209A2 (de) |
| CA (1) | CA3138145A1 (de) |
| CL (1) | CL2021003051A1 (de) |
| IL (1) | IL288252A (de) |
| MX (1) | MX2021014102A (de) |
| SG (1) | SG11202112329RA (de) |
| TW (1) | TW202110425A (de) |
| WO (1) | WO2020234405A1 (de) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024156912A1 (en) * | 2023-01-26 | 2024-08-02 | Ac Immune Sa | Anti-abeta vaccine therapy |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8663650B2 (en) | 2003-02-21 | 2014-03-04 | Ac Immune Sa | Methods and compositions comprising supramolecular constructs |
| KR101236611B1 (ko) | 2005-12-12 | 2013-03-04 | 에이씨 이뮨 에스.에이. | 치료 백신 |
| WO2012020124A1 (en) | 2010-08-12 | 2012-02-16 | Ac Immune S.A. | Vaccine engineering |
| CN103189050B (zh) | 2010-10-26 | 2017-09-29 | Ac免疫有限公司 | 包含通过疏水部分修饰的肽的基于脂质体的构建体 |
| CA2811188C (en) | 2011-09-23 | 2020-04-28 | Andrea Pfeifer | Vaccine therapy |
-
2020
- 2020-05-20 SG SG11202112329RA patent/SG11202112329RA/en unknown
- 2020-05-20 KR KR1020217041697A patent/KR20220010552A/ko unknown
- 2020-05-20 JP JP2021569155A patent/JP2022533422A/ja active Pending
- 2020-05-20 US US17/612,921 patent/US20220226447A1/en active Pending
- 2020-05-20 TW TW109116790A patent/TW202110425A/zh unknown
- 2020-05-20 EP EP20726473.0A patent/EP3972633A1/de active Pending
- 2020-05-20 CA CA3138145A patent/CA3138145A1/en active Pending
- 2020-05-20 AU AU2020277682A patent/AU2020277682A1/en active Pending
- 2020-05-20 WO PCT/EP2020/064172 patent/WO2020234405A1/en active Application Filing
- 2020-05-20 MX MX2021014102A patent/MX2021014102A/es unknown
- 2020-05-20 CN CN202080035690.8A patent/CN113853214A/zh active Pending
- 2020-05-20 BR BR112021023209A patent/BR112021023209A2/pt unknown
-
2021
- 2021-11-18 CL CL2021003051A patent/CL2021003051A1/es unknown
- 2021-11-21 IL IL288252A patent/IL288252A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3138145A1 (en) | 2020-11-26 |
| CN113853214A (zh) | 2021-12-28 |
| US20220226447A1 (en) | 2022-07-21 |
| MX2021014102A (es) | 2022-02-11 |
| IL288252A (en) | 2022-01-01 |
| WO2020234405A1 (en) | 2020-11-26 |
| JP2022533422A (ja) | 2022-07-22 |
| AU2020277682A1 (en) | 2021-12-23 |
| KR20220010552A (ko) | 2022-01-25 |
| CL2021003051A1 (es) | 2022-07-22 |
| BR112021023209A2 (pt) | 2022-01-18 |
| TW202110425A (zh) | 2021-03-16 |
| EP3972633A1 (de) | 2022-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201804255D0 (en) | Macrophage-based therapy | |
| GB201900702D0 (en) | Therapy | |
| IL277851A (en) | Therapeutic vaccines against ABETA | |
| GB201819853D0 (en) | Therapy | |
| GB201910794D0 (en) | Vaccine | |
| IL288237A (en) | Combined treatment | |
| IL288252A (en) | Therapeutic vaccines against abeta | |
| GB201912191D0 (en) | New therapy | |
| GB201802326D0 (en) | Gene therapy | |
| GB201918752D0 (en) | New therapy | |
| GB201906864D0 (en) | Combination therapy | |
| GB201817385D0 (en) | Therapy | |
| EP3760209C0 (de) | Spezifische gentherapie für ischämische läsionsstellen | |
| GB201821207D0 (en) | Immunotherapy therapy | |
| GB201818579D0 (en) | New therapy | |
| GB201814036D0 (en) | New therapy | |
| GB201919177D0 (en) | Novel therapy | |
| GB201912423D0 (en) | Novel therapy | |
| GB201919036D0 (en) | Therapy | |
| GB201916983D0 (en) | Therapy | |
| GB201914848D0 (en) | Therapy | |
| GB201913797D0 (en) | Therapy | |
| GB201913785D0 (en) | Therapy | |
| GB201912524D0 (en) | Therapy | |
| GB201911948D0 (en) | Therapy |